Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotron ( (AU:BIT) ) just unveiled an announcement.
Biotron Limited has successfully completed its non-renounceable rights issue, with the shortfall fully subscribed, resulting in the issuance of 292,666,664 fully paid ordinary shares and 146,333,324 listed options and raising an additional A$878,000, bringing total proceeds from the offer to A$1,523,862 before costs. Together with a A$1 million placement completed in late 2025 and the recent acquisition of Sedarex Limited, the strengthened capital position and shareholder support leave Biotron better placed to advance its expanded and diversified therapeutic portfolio, potentially accelerating its development programs and reinforcing its strategic positioning in the biotech sector.
The most recent analyst rating on (AU:BIT) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Biotron stock, see the AU:BIT Stock Forecast page.
More about Biotron
Biotron Limited is an Australian biotechnology company listed on the ASX that is developing a diversified portfolio of therapeutic candidates, with a focus on advancing its drug programs following the acquisition of Sedarex Limited. The company targets opportunities in high-need therapeutic areas and is supported by both new and existing shareholders in the Australian capital markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.43M
See more insights into BIT stock on TipRanks’ Stock Analysis page.